Stoke Therapeutics, Inc. (STOK)

Stoke Therapeutics Income Statement

Financials in millions USD. Fiscal year is January - December.

Year	2023	2022	2021	2020	2019
Revenue	8.78	12.41	0	0	0
Revenue Growth (YoY)	-29.22%	-	-	-	-
Gross Profit	8.78	12.41	0	0	0
Selling, General & Admin	41.32	38.92	31.9	20.85	11.91
Research & Development	82.23	77.84	54.17	32.2	23.76
Operating Expenses	123.55	116.76	86.07	53.04	35.68
Operating Income	-114.77	-104.36	-86.07	-53.04	-35.68
Interest Expense / Income	-9.91	-3.12	-0.12	0.7	0
Other Expense / Income	-0.17	-0.17	-0.14	-1.5	-3.35
Pretax Income	-104.7	-101.07	-85.81	-52.24	-32.33
Net Income	-104.7	-101.07	-85.81	-52.24	-32.33
Shares Outstanding (Basic)	44	39	37	33	18
Shares Outstanding (Diluted)	44	39	37	33	18
Shares Change	13.10%	5.87%	9.71%	86.34%	2433.56%
EPS (Basic)	-2.38	-2.60	-2.34	-1.56	-1.80
EPS (Diluted)	-2.38	-2.60	-2.34	-1.56	-1.80
Free Cash Flow	-82.68	-35.83	-68.11	-43.27	-32.69
Free Cash Flow Per Share	-1.88	-0.92	-1.85	-1.29	-1.82
Gross Margin	100.00%	100.00%	-	-	-
Operating Margin	-1307.21%	-841.24%	-	-	-
Profit Margin	-1192.47%	-814.73%	-	-	-
Free Cash Flow Margin	-941.72%	-288.82%	-	-	-
EBITDA	-109.88	-100.65	-83.7	-49.62	-31.88
EBITDA Margin	-1251.46%	-811.40%	-	-	-
Depreciation & Amortization	4.73	3.54	2.23	1.93	0.45
EBIT	-114.61	-104.19	-85.93	-51.54	-32.33
EBIT Margin	-1305.32%	-839.90%	-	-	-

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).